VERU stock forecast
Our latest prediction for Veru, Inc.'s stock price was made on the Feb. 21, 2020 when the stock price was at 4.54$.
In the short term (2weeks), VERU's stock price should underperform the market by -0.52%. During that period the price should oscillate between -9.47% and +12.27%.
In the medium term (3months), VERU's stock price should underperform the market by -6.77%. During that period the price should oscillate between -29.45% and +25.57%.Get email alerts
About Veru, Inc.
Veru, Inc. is an oncology and urology biopharmaceutical company. It develops medicines for prostate cancer treatment and prostate cancer supportive care as well as urology specialty pharmaceuticals. Its oncology drug candidates includes VERU-111, an oral alpha and beta tubulin inhibitor, which is in a phase 1b/2 study for the treatment of metastatic castration resistant prostate cancer; Zuclomiphene citrate, which is in a phase 2 clinical trial for the treatment of hot flashes in men undergoing prostate cancer hormonal therapies; and VERU-100, a long-acting GnRH antagonist 3 month subcutaneous depot, planned phase 2 clinical trial for the treatment of hormone sensitive advanced prostate cancer. The company's urology specialty pharmaceutical drug candidate is TADFIN, a tadalafil and finasteride combination oral capsule, for the treatment of men with benign prostatic hyperplasia. Its commercial products include the FC2 Female/Internal condom for prevention of pregnancy and sexually transmitted infections and PREBOOST 4% benzocaine wipes for the prevention of premature ejaculation marketed as Roman Swipes by getroman.com. The company was founded by William R. Gargiulo Jr. and O.B. Parrish in 1996 and is headquartered in Miami, FL.
At the moment the company generates 36M USD in revenues.
On its last earning announcement, the company reported a loss of -0.21$ per share.
The book value per share is 0.65$
Three months stock forecastFeb. 21, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|